Valneva SE
VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.97
Price-2.29%
-$0.12
1Y
Price
Market Cap
$471.272m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-128.5%
EBITDA Margin-150.8%
Net Profit Margin-13.8%
Free Cash Flow Margin-128.5%
EBITDA Margin-150.8%
Net Profit Margin-13.8%
Free Cash Flow MarginRevenue
$156.329m
+6.1%
1y CAGR-13.7%
3y CAGR-9.3%
5y CAGREarnings
-$138.033m
-734.2%
1y CAGR-205.7%
3y CAGR-178.0%
5y CAGREPS
-$1.63
-670.6%
1y CAGR-180.4%
3y CAGR-151.6%
5y CAGRBook Value
$76.779m
$372.401m
Assets$295.314m
Liabilities$209.723m
DebtDebt to Assets
56.3%
-2.7x
Debt to EBITDAFree Cash Flow
-$70.918m
+58.9%
1y CAGR+47.1%
3y CAGR-361.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company